ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2226

Application of Classification Criteria for Psoriatic Arthritis to Patients of the Rotterdam Early Arthritis Cohort

Jos Van der Kaap1, Johanna M.W. Hazes2, M. Vis3, Ilya Tchetverikov4 and Jolanda J. Luime2, 1Rotterdam, Netherlands, 2Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Rheumatology, VU University medical center, Amsterdam, Netherlands, 4Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Abstracts, classification criteria, diagnostic criteria and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Psoriatic arthritis (PsA) poses a diagnostic challenge due to lack of a clear case definition. This has led to varying reports on prevalence, which is held to be 20 to 100 per  100 000 [1-3], while in the past some have even questioned whether PsA should be treated as an individual entity at all[4]. Currently, the distinction between rheumatoid arthritis (RA) and PsA is still defined on clinical grounds. We compared the number of patients clinically diagnosed with PsA with the number meeting currently used classification criteria for PsA in the REACH-population.

Methods: 1216 patients from the Rotterdam Early Arthritis Cohort were used for this analysis. Patients were eligible for REACH with confirmed arthritis in at least 1 joint or 2 painful joints and at least 2 of the following criteria: morning stiffness for more than 1 hour; inability to clench a fist in the morning; pain when shaking someone’s hand; pins and needles in the fingers; difficulties wearing rings or shoes; a family history of RA; unexplained fatigue for less than 1 year. The criteria sets considered were the Classification of Psoriatic Arthritis (CASPAR) criteria [5], the Moll & Wright (M&W) criteria[6], and the European Spondyloarthropathy Study Group (ESSG) criteria for PsA [7]. These sets were applied at baseline using descriptive statistics in STATA12. Inflammatory spinal pain was not measured in REACH and the non-specific presence of low back pain was felt to be inappropriate due to high prevalence in the REACH cohort (50%).

Results: In this cohort 45 (3.7%) patients were clinically diagnosed with PsA, similar to numbers previously reported[8]. In the remaining group, 60 (4.9%) met the CASPAR criteria, 33 (2.7%) met the M&W criteria and 2 (0.2%)met the modified ESSG criteria. Patients satisfying the CASPAR criteria and M&W criteria mainly had a negative Rheumatoid Factor and presence of current psoriasis. Among patients fulfilling the CASPAR criteria (n=60) the most frequent clinical diagnoses were oligo- or polyartritis e.c.i, (n=19), artralgia or myalgia (n=12), osteoarthritis (n=8),  monoathritis e.c.i (n=6) and rheumatoid arthritis (n=5).  For fulfilling the M&W criteria inflammatory arthritis is mandatory, so compared to the CASPAR criteria, patients with artralgia or myalgia did not fulfill these. The ESSG criteria for PsA were met in 2 patients with M.Bechterew and positive family history for PsA.  The total number of patients meeting classification criteria was thus 62, not including patients clinically diagnosed with PsA (n=45).

Conclusion: The number of patients meeting the different classification criteria sets exceeded the total number clinically diagnosed with PsA, emphasizing the diagnostic challenge in this disease.  Out of the used criteria sets, the CASPAR criteria were met in most patients.

1.Shbeeb, M., et al., J Rheumatol, 2000.

2.Veale, D.J. J Rheumatol, 2000.

3.Wilson, F.C., et al. J Rheumatol, 2009.

4.Cats, Rheumatology,  1985.

5.Taylor, W., et al. Arthritis Rheum, 2006.

6.Moll, J.M. and V. Wright, Semin Arthritis Rheum, 1973.

7.Dougados, M., et al. Arthritis Rheum, 1991.

8.van Aken, J., et al. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol, 2003.


Disclosure:

J. Van der Kaap,
None;

J. M. W. Hazes,
None;

M. Vis,
None;

I. Tchetverikov,
None;

J. J. Luime,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/application-of-classification-criteria-for-psoriatic-arthritis-to-patients-of-the-rotterdam-early-arthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology